ABSTRACT-Breast cancer incidence data were analyzed from three populations of women exposed to ionizing radiation: survivors of the Hiroshima and Nagasaki atomic bombs, patients in Massachusetts tuberculosis sanitoria who were exposed to multiple chest fluoroscopies, and patients treated by X-rays for acute postpartum mastitis in Rochester, New York. Parallel analyses by radiation dose, age at exposure, and time after exposure suggested that risk of radiation-induced cancer increased approximately linearly with increasing dose and was heavily dependent on age at exposure; however, the risk was otherwise remarkably similar among the three populations, at least for ages 10-40 years at exposure, and followed the same temporal pattern of occurrence as did breast cancer incidence in nonexposed women of similar ages. -JNCI 65: 353-376, 1980. Public concern about breast cancer risk from exposures to low doses of ionizing radiation (1) and the continuing, unresolved scientific debate about the magnitude of the risks (2) emphasize the many existing uncertainties about the relationship between radiation dose and cancer risk. One may easily overlook the fact that more information is available on the carcinogenic effects of ionizing radiation than on any other important environmental carcinogen. With the recent publication of five major studies of breast cancer incidence in populations of irradiated women (3-7), there has been a remarkable accumulation of information about female breast cancer. Radiation-induced breast cancer has occurred among women with histories of X-ray therapy for acute postpartum mastitis (4, 8), women who received multiple chest fluoroscopies during pneumothorax treatment for TB (5, 9), and female survivors of the Hiroshima and Nagasaki A-bomb explosions (3, 7). In addition, risks of radiation-induced breast cancer have been established (although less securely) among women given X-ray therapy for other benign breast diseases (6). Moreover, the risk estimates associated with these observations reveal that the female breast is unusually sensititive to radiation carcinogenesis (10) .
Public concern about breast cancer risk from exposures to low doses of ionizing radiation (1) and the continuing, unresolved scientific debate about the magnitude of the risks (2) emphasize the many existing uncertainties about the relationship between radiation dose and cancer risk. One may easily overlook the fact that more information is available on the carcinogenic effects of ionizing radiation than on any other important environmental carcinogen. With the recent publication of five major studies of breast cancer incidence in populations of irradiated women (3) (4) (5) (6) (7) , there has been a remarkable accumulation of information about female breast cancer. Radiation-induced breast cancer has occurred among women with histories of X-ray therapy for acute postpartum mastitis (4, 8) , women who received multiple chest fluoroscopies during pneumothorax treatment for TB (5, 9) , and female survivors of the Hiroshima and Nagasaki A-bomb explosions (3, 7) . In addition, risks of radiation-induced breast cancer have been established (although less securely) among women given X-ray therapy for other benign breast diseases (6) . Moreover, the risk estimates associated with these observations reveal that the female breast is unusually sensititive to radiation carcinogenesis (10) .
Still uncertain are the precise levels of risks associated with various dose levels (especially the low-dose levels characteristic of mammography); the shape of the dose-response curve; the effects of dose fractionation, protraction, and radiation quality (LET); the influence of age and other characteristics of the subject at the time of exposure; and the temporal distribution of risk following exposure. The results of various individual studies are highly informative with respect to many of these questions, but intriguing inconsistencies also exist. For example, the overall estimates of risk per rad from two recent studies of A-bomb survivors (3-7) are considerably lower than those from three recent studies of medically exposed populations (4) (5) (6) . Also, two of the medical series suggest a dependence of latency period on dose (4, 6) , whereas the fluoroscopy series and the two A-bomb survivor series do not (3, 5, 7, 11, 12) . For one to suggest reasons for these and other differences is easy (e.g., by ascribing them to differences in susceptibility between Japanese and Western women, to age differences among the irradiated populations, or to confounding between dose and age), but without new data analyses these suggestions remain mere speculations. By extensive reanalyses of the original data from several large studies, the present paper differs from earlier reviews of published works linking breast cancer risk and radiation exposure. Whereas many of the conclusions reached are expected to be identical to those reached in earlier reviews or original studies, the empirical bases for such conclusions should be clearer.
Besides availability of the original data, certain requirements must be met for a meaningful parallel reanalysis of data from several studies by use of identical methods and assumptions. There must be sufficient years of follow-up and numbers of subjects and high enough dose levels so that statistically stable risk estimates can be obtained even after subdivision of the data by age and other factors. For contrast in terms of dose there must be a valid comparison group or a broad range of radiation dose and, preferably, in-ABBREVIATIONS USED: ATB = a t time of bombing; df = degrees of freedom; LET=linear energy transfer; LSS=life-span study; RBE=rela-tive biologic effectiveness; RERF = Radiation Effects Research Foundation; TB = tuberculosis; WY = woman-years. dividual measurement of dose for each study. These requirements are best satisfied by the 1950-74 LSS sample incidence study by Tokunaga et al. (7) , the Massachusetts TB-fluoroscopy study by Boice and Monson (5) , and the recent analysis of the Rochester, New York, mastitis series, with nonexposed mastitis and sibling controls reported by Shore et al. (4) .
MATERIALS AND METHODS
Basic data, including numbers of cases and WY of observation for risk, are given in Appendix table [1] [2] [3] by age at exposure (or age at beginning of exposure), by radiation dose interval, by calendar time after exposure (excluding the first 5 yr), and by city for Abomb survivors. Such detail is necessary to account for differences among the three studies that may be artifactually related to the risk estimates given in the original papers. Except for certain comparisons requiring tabulation of data by both age at exposure and age at risk, the analyses described in this paper can be reconstructed with the use of the data in Appendix table 1-3. Differences in age and dose distribution among the three studies are summarized in text-figure I. The selected nature of the two medical series and the unselected nature of the LSS series are reflected in the age distributions. The dose distributions illustrate the substantially greater number of A-bomb survivors exposed at low doses. At high-dose levels the three series are based on similar numbers.
Certain differences exist among the three populations represented in Appendix tables 1-3 that were not addressable by analytic methods. The LSS series was ascertained by examinations of death certificates, clinical records, and pathologic materials from hospitals, • 8 university medical schools, and tumor and tissue registries in Hiroshima and Nagasaki. Whereas the death certificate data were complete, migration of survivors, especially the younger ones, from the two cities since 1950 (the date of the census on which the LSS sample was based) was likely to have caused overall underascertainment of incidence (3) . Migration was not different among dose categories (13) nor did evidence exist of ascertainment bias with respect to dose (3) . The most probable effect of the migration is a slight downward bias in estimated risk.
A more speculative consideration is that TB in young patients who were frequently fluoroscoped may have been associated with underweight. Age at menarche is related both to fatness (14) and to breast cancer risk in later life (15) . TB patients therefore conceivably could be a low-risk group, although no decreased risk was apparent among the nonexposed patients (5). However, whereas the experience of the 3 comparison groups (nonirradiated mastitis patients and sisters of irradiated and nonirradiated patients) for the mastitis series effectively minimizes the possibility that the observed radiation dose response was an artifact of the treated condition (4), the response to radiation of lactating or inflamed tissue might differ from that of other breast tissue.
Dose estimates were more reliable for patients given radiation therapy than for patients given multiple fluoroscopic examinations or for A-bomb survivors. Dose estimation for both pneumothorax patients and A-bomb survivors had to be based on reconstructions of their exposures (16, 17) . Jablon (18) estimated the standard errors of individual estimates for the LSS sample to be ±30%. He suggested that the higher dose estimates probably tended to be biased upward, whereas the lower estimates were probably biased downward. that is, L is the linear form, LQ the linear-quadratic form with upward curvature, L-K the form with downward curvature, and LQ-K the most general form, with upward curvature at low-dose levels and downward curvature at high-dose levels. We also considered pure quadratic variants of LQ (Q) and LQ-K (Q-K) above, i.e., functions in which the linear term was assumed to be zero:
These functional forms were, however, thought to be inappropriate for estimation of low-dose risk: Although the models with linear terms might yield small lowdose risk estimates, this must necessarily occur when the linear coefficient is assumed to be zero. They were included mainly for completeness, as a check on the adequacy of the other forms.
The curve-fitting method, for which technical details can be found in (22, 23) , is an iterative weighted leastsquares procedure. On any given iteration, the weight corresponding to the observed rate (simple or agestandardized) at dose D is assumed to be the number of curvature at low-dose levels (a2) and downward curvature at high-dose levels ({31 and {32). The constraint that all parameters be nonnegative has its basis in radiobiologic theory. The linear coefficient al represented that part of the carcinogenesis response that was proportional to dose, i.e., the probability of a single ionizing event at a given locus in a cell nucleus. For low-LET radiation such as gamma ray or X-ray, ionizing events were sparsely distributed along a radiation track, and the probability of two closely spaced events was proportional to the square of dose. The quadratic coefficient a2 represented the additional effect of two closely spaced events as compared to a single ionization, and this additional effect cannot be negative. The coefficients {31 and {32 were similarly defined, but with respect to the competing effect of cell killing, which removed cells that might otherwise be involved in carcinogenesis.
Because a statistical trade-off existed between the number of parameters fitted and the accuracy of the parameter estimates (with the assumption that the model was true), parameters a2, {31, and {32 were retained in the model only if their inclusion significantly improved the fit of the model to the data. In fact, we found that nothing was gained and considerable precision was lost by the inclusion of both {31 and {32 in the above form. Of the two, {31 accounted for less variation and so was dropped.
For simplification of references to the various versions of 1(D) in the text, they are denoted as follows:
[Q]
The most obvious difference among the three studies is the great difference in natural age-specific breast cancer incidence in Japan and the United States (text- fig. 2 ) (19) . The data in Appendix tables 1-3, therefore, provided the basis for a test of whether the effect of radiation on breast cancer incidence was influenced by natural cancer rates.
The dependence of breast cancer risk on radiation dose has been shown to vary by age at exposure (3, 5, 7) . The age-specific data were generally too sparse, however, for fitting any but the simplest dose-response functions. As a way around this dilemma, we assumed that within a given population, the shape (but not necessarily the magnitude) of the dose-response function for breast cancer was independent of age at exposure. Given this assumption, the shape of the dose-response curve for each population should be obtainable from an investigation of summary rates, standardized for age at exposure to adjust for possible confounding of age with radiation dose.
The functional forms fitted to the dose-response data from the three main studies considered in this report are special cases of the general form:
where I(D) is the incidence of breast cancer at dose D (radiation dose in rads) and where the parameters ao, ai, a2, {31, and {32 are constrained to be nonnegative. This functional form, discussed by Brown (20) and Upton (21) , can be viewed as basically a linear function (with ao and al being essentially the only parameters relevant to risk at very low dose levels) with modifications that allowed the fitted curve to express upward We obtained identical fitted curves by using the above function and a restricted form in which the parameter (X2 was assumed to be zero (denoted L-L) (table 2). The estimated ratio of the linear coefficients for neutron and gamma dose was 1.42±1.86 under the L-L model. Thus the linear model RBE for neutrons was estimated to be close to I, and with 95% confidence to be less than 4.48. The data do not suggest a purely quadratic dose response for gamma rays; restricting the linear coefficient (Xl in I(D')', D n ) to zero (the Q-L model) yielded a fitted curve with a significantly poorer fit to the data than did the LQ-L model (P = 0.003). This result is in marked contrast to the results of similar curve-fitting analyses of leukemia incidence data, in which the Q-L model appears to fit the data as well as does the L-L model (29, 30) .
The L, Q and LQ functions of rem dose equivalents were fitted separately to Hiroshima and Nagasaki rates for different RBE assumptions, including constant RBE values of I, 1.42, and 5 and the variable RBE corresponding to the Q-L analysis in table 2, RBE = 40.7/Dn~(table 3). In all cases for which the RBE was assumed to be constant, the Land LQ models yielded closely similar fitted functions that agreed significantly better with the data than did the fitted function corresponding to the Q model. Even for the variable RBE assumption, under which risk should be proportional to the square of rem dose, the fit of the Q model was only marginally better than that of the L model, worse than that of the LQ model in the case of Hiroshima, and significantly worse than the fit of the Land LQ models for Nagasaki.
For constant RBE values of I and 1.42 very little difference was found between the two cities with WY at that dose (usually the number of WY corresponding to a dose interval with average dose D) divided by the current value of the fitted function at dose D; i.e., the rate times the WY is assumed to correspond approximately to a Poisson variate with mean equal to the incidence predicted by the product of the fitted function times the WY at risk. In practice 2 '
X values for lack of fit seemed somewhat smaller than would be expected on the basis of random variation, given a true dose-response model. This observation suggested that the true variances may be slightly smaller than the assumed values. However, no reason was found to believe that the weights are incorrect for curve fitting.
RESULTS AND DISCUSSION

RBE of Neutrons
The large size of the LSS sample and its relative strength at low-and intermediate-dose levels make it the most suitable basis for inferences about the shape of the dose-response curve. Whereas the breast tissue of japanese and American women may respond differently to radiation, the assumption will be made that these differences might involve the magnitude of the response but not the shape or functional form of the dose-response curve. A major objection to this assumption is the difference in the types of radiation received by the exposed women in the two U.S. medical series and by the japanese A-bomb survivors. Although almost all of the radiation received by the Nagasaki survivors was in the form of gamma rays, comparable to the X-rays received by the U.S. women, the radiation from the Hiroshima bomb contained a neutron component amounting to 13-30% of the total absorbed dose in breast tissue. Because experiments in animals have suggested different dose-response curves for gammaand neutron-induced tumors (24) (25) (26) (27) (28) , evaluation of any differences in dose response between the two cities is important.
This question was addressed by fitting to the dosespecific breast cancer rates for Hiroshima and Nagasaki, standardized to the age distribution of the combined cities (table I), a function linear-quadratic in gamma dose (D')') and linear in neutron dose (D n ) , denoted LQ-L for brevity:
In this function all parameters are constrained to be nonnegative, and the intercept (Xo is allowed to be different for the two cities. Radiobiologically, no dosesquared term in D'; is needed because closely spaced ionizing events are the rule; i.e., the probability of two events in a given locus is approximately the same as that of a single event. The additional complexity of cell killing was not introduced because it would have added too many parameters. However, no evidence was found of a high-dose reduction in slope consistent with cell killing. C The best-fitting parameter value would be negative; the value of zero results from the prior constraint that the parameter be nonnegative, Constraints are not accounted for in computation of error estimates for the parameter estimates. Therefore, error estimates may be misleading if, as in this case, there are active constraints on any of the parameters of the fitted function. For the data considered in this paper, however, the error estimates for the remaining parameters appear to be little affected by the presence of an active constraint; similar error estimates were obtained when the active constraints were removed. Whereas the above analysis cannot be said to resolve the question of the RBE of neutrons with respect to breast cancer in women, little evidence exists to indicate that the breast cancer responses to exposure to gamma and neutron radiations were different. Accordingly, a simple pooling of the Hiroshima and Nagasaki data under the assumption of equivalence in carcinogenic effectiveness between neutron and gamma radiation exposures to the breast introduced no apparent bias.
Dose Response
In the analyses described below it was assumed that whereas the overall level of the breast cancer response to irradiation may depend on age at exposure, so that care must be taken to avoid confounding of dose and age, the shape of the dose-response function does not depend on age. This assumption allowed the data to be pooled by standardizing dose-specific incidence rates according to a standard age distribution. For each series, the overall age distribution for that series was used as a standard. for f3d, whereas LQ-K was not a noticeable improvement over L-K (P = 0.30 for 0:2). Of the four main functional forms considered, therefore, only the linear form L could be fitted to the numerically strongest data set, but some support was given to the existence of high-dose downward curvature by the New York mastitis data.
A stronger result was obtained with single-breast data from the mastitis series (table 7, text-fig. 7 ). For these data the downward-curving form L-K gave an improved fit over the linear form L (P=0.02), which suggested that cell killing at high-dose levels (400-1,400 rads) may be a factor of some importance for unfractionated and relatively unfractionated exposures. Neither the Massachusetts fluoroscopy study (5), the earlier Nova Scotia series (9) , nor the LSS study (7) suggests dose-response relationships in which breast cancer CSee footnote e, table 2.
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incidence decreases at high-dose levels. The Massachusetts patients received cumulative doses to the breasts as high as 1,000 rads, and some of the Nova Scotia patients received doses as high as several thousand rads. The highly fractionated nature of the fluoroscopy exposures possibly could explain the absence of a high-dose downturn in observed incidence in these studies, if indeed the mastitis curve truly reflects the underlying dose-response relationship. The LSS dose-response curve, however, cannot be said to reflect any fractionation of dose. Nevertheless, the fact remains that one of the three data sets considered in detail here suggests the existence of downward curvature of the dose-response curve at high-dose levels. Tables 4-6 also give the results of regressions with models Q and Q-K, in which the linear coefficients in models LQ and LQ-K, respectively, were assumed to be zero. These models did not fit the age-standardized data as well as did the corresponding models with linear terms. The data set strongest at the low end of the dose scale, the LSS series, gave the least support to these models, whereas the mastitis series, which is weak at doses between 0 and 100 rads, discriminated only poorly between models L-K and Q-K. Overall, the analysis provides empirical support, as far as breast cancer is concerned, for the presumptive position that low-dose risk estimates should not be based on doseresponse models lacking a linear term.
Age at Exposure
Case reports of breast cancers occurring in young women with histories of high-dose radiation therapy to the chest during infancy have been interpreted as examples of radiogenic cancer because of the high 
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levels of radiation exposure involved and because breast cancer is so rare in young women (31, 32) . Substantial evidence from controlled studies of increased breast cancer risk in women exposed to ionizing radiation before the age of 10 years is lacking, however. Only I (nonexposed) breast cancer was found among women 0-9 years old ATB in the 1950-69 LSS series (3). Five cancers in women of the same age group were found in the 1950-74 series, including I with a breast tissue dose of 57 rads and 4 with less than 10 rads (7). However, this cohort is only now reaching the ages at which the radiation-related excess in the cohort of women 10-19 years old ATB became apparent (3). Another 5-10 years of follow-up should determine the extent to which radiation exposure has affected breast cancer incidence in the youngest cohort. Relative risks for 100 or more rads versus 0 rad by age at exposure are given in table 8 for the LSS, the Massachusetts fluoroscopy study, and the New York mastitis series. For women exposed between 10 and 39 years of age, the relative risks for the three series are mutually supportive in that each strengthens the evidence for a radiation dose effect on breast cancer incidence in women exposed at these ages. The picture is less clear, however, for women older at the time of exposure. The Rochester mastitis data suggest a high relative risk for women 40-44 years of age at time of exposure, but the numbers are small (3 cases among 14 irradiated patients). The Massachusetts fluoroscopy data for women 40-49 years of age at first exposure are especially weak, inasmuch as there were only 58 exposed women and the case numbers in each exposure group are less than expected according to population rates. Neither medical series contains any information about risk for women exposed at older ages.
The real problem, however, is that the numerically strong LSS data are contradictory. The high but statistically nonsignificant relative risk for women 50 years or older ATB is based on relatively small numbers. However, a statistically significant relative risk was observed in the 1950-69 LSS series, from virtually the same information, in which the high-dose interval was defined in terms of kerma rather than dose to breast tissue (2':100 rads kerma~2':75 rads dose to breast) and therefore included 1 more case. Against this must be set the unexpected absence of any dose effect in the cohort of women 40-49 years old ATB. This anomaly, which also occurred in the 1950-69 LSS series but was not detected in the analysis because different age intervals ATB (20-34 and 35-49 yr of age) were used (3), occurred in both cities.
The deficit among A-bomb survivors who were 40-49 years of age ATB could conceivably have been due to the effects of irradiation on the ovaries at ages associ- ated with marked changes in ovarian function. Sawada (33) found that among 880 exposed women post menarche and prior to menopause, one-half experienced amenorrhea after the bombings. This condition was particularly marked among women in their forties. Amenorrhea in women of 34 years of age or under was transient in every case, but among those 45-49 years of age it was permanent and continued to menopause in over 80%. Women treated with X-irradiation for metropathia hemorrhagica at Scottish radiotherapy centers between 1940 and 1960 and who were in their 40's when irradiated later had less than one-half the breast cancer mortality expected according to population rates (34) . However, no such reduction in breast cancer incidence was found among a somewhat older and much smaller group of women in whom artificial menopause was induced by X-irradiation (35) . Doses to ovaries were about one-half as great as doses to breast tissue among A-bomb survivors and amounted to about a 100-rad average dose to ovaries among survivors with 100 rads or more to the breasts (36) . Doses were on the order of several hundreds of rads in the two series of women given therapeutic pelvic irradiation. At any rate, the findings for women in the LSS series exposed between the ages of 40 and 49 years considerably complicate the problem of risk estimation for women with breast tissue exposure at these ages.
If doubts about the appropriateness of population controls for the Swedish radiation therapy series (6) could be resolved, the evidence from that study might argue strongly for an increased risk of breast cancer among women exposed to radiation at ages over 40 years. Statistically significant excess incidences, compared with population rates, were found at all ages in women at time of radiation exposure including those 40-49 and 50 years of age or older.
Latency Period
"Latency period" is used here to denote elapsed time between a radiation exposure and the diagnosis of a breast cancer caused by that exposure; i.e., the definition is conditional on a breast cancer having occurred and is therefore different from the definition used in competing risk analysis in which the latency period may extend considerably beyond the normal length of life (37) . Although not directly observable, latency period can be studied by comparison of the temporal distribution of breast cancer incidence occurring in a high-dose group having a high and statistically significant relative risk (and therefore, presumably, a high proportion of radiation-caused cancers) and in an appropriate low-dose control group.
Individual diagnosis dates for breast cancer cases are not different, on the average, between high-dose (2100 rads) and low-dose (nonexposed and 0-9 rads) groups in the LSS series for any age interval. Distributions with respect to date of diagnosis, in the form of cumulative incidence curves, are compared in text- half of the high-dose cases were radiation related. Even so, there were only 4 low-dose (nonexposed) breast cancer cases in the cohort of Massachusetts patients exposed at 10-19 years of age, and therefore a curve based on population rates was substituted for the lowdose curve. The curves offer no support to the hypothesis that radiation-induced breast cancers tend to occur earlier than do other breast cancers; in fact, they suggest that although radiation may increase the lifetime risk of breast cancer, its age distribution is unaffected. This conclusion also resulted from earlier and more detailed analyses (presented elsewhere) of data from the 1950-69 and 1950-74 LSS sample series (11, 12) ; the result is in marked contrast to the wavelike temporal pattern observed for radiation-induced leukemia. The present analysis shows that the temporal patterns of breast cancer incidence in the two medical series also are unaffected by dose. The association between dose and latency period reported by Shore et al. (4) did not appear in the present analysis in which age at exposure was specifically taken into account. The association reported by Baral et al. (6) may have a similar explanation; in that series dose and age at exposure clearly are correlated. The existence of a minimal latency period, during which no excess risk occurs, is suggested by consideration of the time required for a tumor to reach a clinically detectable stage. In view of the preceding paragraph, the concept may be relevant only to women already at or near ages of nonnegligible natural breast cancer risk at the time of exposure. Because breast cancer incidence increases with advancing age and because the available evidence for increased risk in women exposed at ages over 40 years is either nonexistent (for the LSS cohort 40-49 yr of age ATB) or based on small numbers (for the LSS cohort~50 yr old ATB and, in the two medical series, for women 40-44 yr of age at first exposure), there is probably a built-in bias toward overestimation of the minimal latency period. The Rochester mastitis data show statistically significant high-dose excesses of breast cancer 10-14 years after treatment and, more strongly, 20-24 and 25-29 years after treatment, but a high-dose deficit occurred for the period 15-19 years after treatment. Data from the generally younger Massachusetts fluoroscopy series first show a statistically significant excess 15-19 years after first exposure, which continues during later periods. The age-adjusted relative risk for 5-9 years after exposure is high but not statistically significant for the 1950-74 LSS series; the relative risks remain fairly constant, whereas the P-values decrease rapidly for subsequent 5-year periods (P=0.051 for 1955-59). However, the 1950-69 LSS data, which for the earliest years of follow-up are essentially the same as those of the most recent series except for different dose cuts, yielded a statistically significant excess (for~100 rads kerma) for years 5-9 after 1945. No data are available for the period 1945-49. In view of these results and the above suggestions of possible upward bias, it seems reasonable to assume a minimum latency period of Radiation-Induced Breast Cancer 363 about 5 years for women 25 years old or older at exposure. However, a further period of perhaps 5 years may be required before there is substantial expression of the excess risk.
The existence or nonexistence of a maximum latency period (and therefore a delimited risk "plateau") cannot be determined from the available data, except that if one exists it must be greater than 30 years.
Age-Specific Risk Estimates
Linear estimates of absolute and relative risk for each series and each age at exposure represented in Appendix tables 1-3 are shown in table 9 and text-figure 9. The estimates are for risk following a minimum latency period (before substantial expression of risk) of 10 years for women 20 years or older at first exposure and 15 and 20 years for women 15-19 and 10-14 years old, respectively, at first exposure.
Remarkably, the absolute risk estimates for women exposed at ages 10-19, 20-29, and 30-39 years are similar among the three studies. Younger japanese women appear to be as sensitive to radiation as are Western women in terms of absolute risk for radiogenic breast cancer. In terms of relative risk, the effect on japanese women is, of course, greater inasmuch as they have approximately the same absolute risk as Western women but have a much lower natural breast cancer risk (text- fig. 2 ).
The negative risk coefficient for the LSS cohort of women 40 to 49 years old ATB underlines the complete absence of a dose reponse in this group. more years of age ATB serves only to confuse the situation further. The extremely high coefficients for the Rochester mastitis patients 40-44 years of age at treatment are based on only 3 breast cancers among 14 exposed patients and do not, therefore, strongly suggest that the breast tissues of older women in this series were more sensitive to radiation than were those of younger women. They do, however, suggest that sensitivity to radiogenic breast cancer did not markedly decrease with increasing age at exposure. Unless some unknown artifact is responsible for the lack of a response in the LSS cohort of women 40-49 years of age ATB (and the negative risk coefficients might suggest the existence of such an artifact), the Japanese and American populations covered by these studies appear to differ in their breast cancer response to radiation received after the age of 40 years. The difference, if real, could be due to an effect of wholebody radiation on ovarian function or to some other factor.
The Swedish radiation therapy study of Baral et al. (6) reported a decreasing excess risk per rad, as compared to population rates, with increasing age at treatment. Dose was highly correlated with age at treatment, however, and average doses were very high: 285, 437, 667, 886, and 995 rads for women treated at ages 10-19, 20-29, 30-39, 40-49 , and 50 or more years, respectively. It is not possible to tell if the variation in risk per rad by age at treatment was due to differences JNCI, VOL. 65, NO.2, AUGUST 1980 in sensmvity, to a high-dose cell killing effect like that suggested by the analysis of table 7 and text-figure 7, or even to variations by age with respect to the diseases treated.
Relative Versus Absolute Risk Models
Breast cancer risk depends on a woman's age at the time of observation; for women with histories of radiation exposure, risk may also depend on the age(s) at which the exposure occurred. Available data are far too sparse to yield reliable risk estimates calculated separately for specific combinations of age at exposure and age at risk. It is therefore convenient to assume that a woman's risk at one age has a simple relationship to her risk at another age on the basis that she received a certain radiation dose at a given age. An absolute risk model implies that the risk of breast cancer at a given age is the sum of the natural risk at that age plus a dose-dependent increment, which may depend on age at exposure but not on age at risk. The arithmetic difference between the risks for exposed women and otherwise similar nonexposed women remains constant over time. A relative risk model, however, expresses the probability of cancer at a given age as the product of the age-specific natural risk times a factor depending on dose and age at exposure. If incidence data based on a relatively short follow-up of women irradiated at young ages are used to estimate excess lifetime risk of breast cancer and if the natural incidence of breast cancer increases with advancing age throughout a woman's lifetime, then lifetime risk estimates based on relative risk models will tend to be greater than estimates based on corresponding absolute risk models. The correctness of either approach depends, of course, on the degree to which it represents the action of the unknown carcinogenic mechanism.
Differences and ratios of breast cancer rates observed among women exposed to high doses (2:100 rads) in each of the three series versus the appropriate population rates are shown in table 10 and text-figure 10 by age at risk for different ages at exposure. Although these data are not conclusive, they suggest that the rate ratios are at least as stable over time as the rate differences and perhaps more so. For the projection of risk to the end of life, or otherwise beyond the period of follow-up in these and other studies, it seems at least as appropriate to use the relative risk model as the absolute risk model. However, virtually no information has been found on whether the excess breast cancer risk due to radiation exposure extends until the end of life. Such information is conspicuously lacking for women exposed at young ages for whom this excess has been high in both absolute and relative terms over the period of follow-up observed so far. A logical inconsis-
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tency occurs between the inference that relative risks may be constant over time following exposure and the inference that absolute risk may be invariant among populations exposed at similar ages but having different background breast cancer rates. As shown in textfigure 2, age-specific breast cancer rates for japanese women differ markedly from those of American women, especially at postmenopausal ages. If absolute risks over the first 30 years of follow-up are equal for japanese and American women exposed between the ages of 10 and 19 years, they should not, according to the relative risk projection model, be equal over the remainder of life. This contradiction, which conceivably could reflect ongoing changes in the age-specific breast cancer rates for japan, is more likely to be an indication that neither the hypothesis of equal absolute risks for different irradiated populations of similar ages nor the hypotheses of constant relative risk over time is strictly true. Both hypotheses are extremely simple, and though each may be more nearly true than other equally simple hypotheses, they probably can be pushed too far. Further follow-up of the three exposed populations considered here should yield further insights.
CONCLUSIONS
Breast cancer incidence data from three large popula- tions of irradiated women have been analyzed in parallel with respect to radiation dose. Particular attention has been paid to possible differences in dose response associated with radiation quality (neutrons vs. gamma rays), fractionation of dose, age at exposure, time after irradiation, age at observation for risk, and population differences in natural breast cancer risk. The analyses confirmed the conclusions reached in earlier studies, including the original studies from which the present data were obtained. The analyses of age-adjusted breast cancer rates showed the dose-response curves to be consistent with linearity and provided little evidence of departures from linearity consistent with current radiobiologic theory. An analysis of Hiroshima and Nagasaki rates revealed little difference between the two cities regarding dose response, a finding consistent with approximate dose equivalence of neutrons and gamma rays with respect to radiation-induced breast cancer in women.
The age-specific analyses confirmed 1) the higher risk per rad after ages of normally high incidence were reached in women irradiated between the ages of 10 and 20 years and 2) the absence of any association between dose and risk previously reported for A-bomb survivors exposed between the ages of 40 and 49 years. This finding, the possibility of artifactual explanations related to whole-body exposure, and the paucity of data corresponding to comparable ages in the other two series limit the age-specific generalizations possible from this study to the age range of 10-39 years at time of exposure. For intervals of age at exposure for which two or more series had sufficient data to compute risk estimates, i.e., 10-19, 20-29, and 30-39 years, estimates of absolute excess risk per rad were remarkably uniform across studies.
No association was found between dose and time from exposure until diagnosis of breast cancer for any of the three series; the temporal pattern of occurrence for radiation-attributable breast cancer appeared to be similar to that for breast cancer not attributable to radiation, e.g., in comparable low-dose group or nonexposed group or in the general population. In keeping with this observation, relative measures of excess risk due to radiation exposure appeared to be more stable over time than did absolute measures of risk. The relative risk model thus appeared to be more suitable than the absolute risk model for the projection, if not to the end of life, at least beyond the 30 or more years of follow-up represented by the data analyzed in this paper. Both projection models were used to estimate lifetime excess risk associated with the use of mammography in an earlier, more summary-type report based on these analyses (38) .
The most significant finding of this study undoubtedly is that of linearity of the dose response for radiation-induced breast cancer. This finding is not based merely on linearity or near linearity of the observed dose-response curves. The approximate dose equivalence of gamma and neutron radiations is inconsistent with theoretical mechanisms of biologic effect requiring multiple, closely spaced ionizing events; the alternative, that a single ionizing event may eventually result in breast cancer, is consistent with linearity (39). The finding of approximately equal excess risks per rad for women of similar ages at exposure but with very different patterns of exposure-from the A-bomb survivors with a single exposure to the mastitis patients with 1-11 exposures to the TB patients with 100 or more exposures-also is strongly suggestive of linearity. The dose-response curve for multiple, widely spaced, low-dose exposures to low-LET radiation might be expected to be linear to the extent that the effects of separate ionizing events are independent; e.g., independence would obtain if a single ionizing event could result eventually in cancer or if the effects of spatially separated ionizing events were subject to prompt repair. Only the first of these possibilities, however, is consistent with approximate equivalence of effect between a single 100-rad exposure and 100 temporally separated I-rad exposures. This approximate equivalence, because it involves three distinct irradiated populations, seems unlikely to be coincidental. Brown (40) previously remarked on the similarity of risk estimates based on earlier breast cancer series and its implication for linearity.
Only approximate linearity is claimed to hold. Some degree of curvilmearity is consistent with these data, and in one of the three series there was a suggestion of a high-dose downturn in the dose-response relationship. It is claimed, however, that any true deviations from linearity probably are not so marked as to cause estimates obtained under the assumption of linearity to be seriously wrong. Thus, for example, the age-specific linear regression coefficients in table 9 are estimates not only of the average risks per rad for exposures over the dose ranges represented by the data, which they would be even if the true dose response function were nonlinear, but also of the excess risk from a single 1-rad exposure, a status they could have only under linearity.
The second most significant finding concerns the temporal pattern after exposure of radiation-induced breast cancer and its relationship to age-specific population risk patterns. There are too few data on women exposed at older ages, and follow-up for women exposed at younger ages is too short to tell whether the observed relationships hold throughout life. A possible conclusion is that radiation-induced breast cancer is subject to many, if not all, of the factors that determine the occurrence of breast cancer in unirradiated populations. If, as it seems, the appearance time of a radiation-induced breast cancer is determined by hormones or other host factors that also determine the appearance time of other breast cancers, perhaps the timing of "primary" causes of breast cancer, other than radiation, also has little to do with the time of diagnosis. If radiation exposures between the ages of 10 and 19 years produce more breast cancer than do equivalent exposures at later ages and if the resultant excess risk continues until late in life, maybe the causal events for a disproportionate number of breast cancers among unirradiated women occur during adolescence and early life, as suggested by MacMahon et al. (15) .
Finally, some of the findings of this analysis, in particular the crucial finding of equivalent age-specific risk estimates over the range of ages 10-39 years at time of exposure from the three study populations, could not have been deduced from the original published studies. Where other such parallel reanalyses of doseresponse data from different studies are possible, they seem definitely worthwhile. Total  1  2  1  0  2  0  1  0  0  0  7  Total  1950--54  1  1  2  1  0  0  1  0  0  0  6  1955--59  4  1  2  0  1  0  2  1  0  0  11  1960--64  3  2  2  1  2  0  1  0  0  0  11  1965--69  6  1  0  2  2  2  3  1  1  3  21  1970--74  9  2  0  0  0  2  3  3  0  0  19  Total  23  7  6  4  5  4  10  5  1  3  68 Radiation-Induced Breast Cancer 373 APPENDIX -74  5  2  2  1  0  1  2  1  0  2  16  Total  18  2  3  1  3  3  3  1  0  4  38 
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